BACKGROUND: Huntington's disease (HD) is a progressive, neuropsychiatric disorder, and limited reports indicate that risperidone might improve motor and psychiatric functioning for these patients. METHODS: In a retrospective, chart review study to evaluate the effectiveness of risperidone on motor, psychiatric, and cognitive functioning in HD, 17 patients taking risperidone in the course of clinical care and 12 patients not taking any antipsychotic medication were compared across a year. RESULTS: Patients taking risperidone demonstrated significantly improved psychiatric functioning and motor stabilization, whereas patients not taking risperidone were stable psychiatrically and worsened motorically. CONCLUSIONS: Although controlled clinical trials are clearly needed, these preliminary results support the use of risperidone in patients with HD in treating their psychiatric and possibly motor symptoms.
BACKGROUND:Huntington's disease (HD) is a progressive, neuropsychiatric disorder, and limited reports indicate that risperidone might improve motor and psychiatric functioning for these patients. METHODS: In a retrospective, chart review study to evaluate the effectiveness of risperidone on motor, psychiatric, and cognitive functioning in HD, 17 patients taking risperidone in the course of clinical care and 12 patients not taking any antipsychotic medication were compared across a year. RESULTS:Patients taking risperidone demonstrated significantly improved psychiatric functioning and motor stabilization, whereas patients not taking risperidone were stable psychiatrically and worsened motorically. CONCLUSIONS: Although controlled clinical trials are clearly needed, these preliminary results support the use of risperidone in patients with HD in treating their psychiatric and possibly motor symptoms.
Authors: Steven G Potkin; Georges M Gharabawi; Andrew J Greenspan; Ramy Mahmoud; Colette Kosik-Gonzalez; Marcia F T Rupnow; Cynthia A Bossie; Michael Davidson; Victoria Burtea; Young Zhu; Jintendra K Trivedi Journal: Schizophr Res Date: 2006-06-21 Impact factor: 4.939
Authors: Leigh J Beglinger; Douglas R Langbehn; Kevin Duff; Laura Stierman; Donald W Black; Carissa Nehl; Karen Anderson; Elizabeth Penziner; Jane S Paulsen Journal: Biol Psychiatry Date: 2006-07-12 Impact factor: 13.382
Authors: K Marder; H Zhao; R H Myers; M Cudkowicz; E Kayson; K Kieburtz; C Orme; J Paulsen; J B Penney; E Siemers; I Shoulson Journal: Neurology Date: 2000-01-25 Impact factor: 9.910
Authors: Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman Journal: J Clin Psychiatry Date: 2003-02 Impact factor: 4.384